This Washington Post article based on a news release is a bit skimpy on the details – no mention of costs, side effects, or study limitations. It also hypes the benefits of a drug combination that weren’t studied here and whose effectiveness is unknown.
It’s hard to argue with the conclusion here, but the messaging would have been stronger with some numbers and an independent expert voice.
This business story checked some of our boxes, but fell short on the key criteria that we think readers needed in this discussion of new Alzheimer’s drugs.
A poor-quality news release spawned weak coverage from the CBC, which is paraphrased here by Fox with even less context and nuance. Failure on many levels.